Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.

Saved in:
Bibliographic Details
Title: Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer.
Authors: Nanjo S; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.; Division of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa, Japan., Wu W; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Karachaliou N; Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain., Blakely CM; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Suzuki J; Department of Physiology, UCSF, San Francisco, California, USA., Chou YT; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts, USA., Kerr DL; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Olivas VR; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Shue J; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Rotow J; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Mayekar MK; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Haderk F; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Chatterjee N; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Urisman A; Department of Pathology, UCSF, San Francisco, California, USA., Yeo JC; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore., Skanderup AJ; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore., Tan AC; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Tam WL; Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore., Arrieta O; Thoracic Oncology Unit, National Cancer Institute (INCan), México City, Mexico., Hosomichi K; Department of Bioinformatics and Genomic, Kanazawa University, Kanazawa, Japan., Nishiyama A; Division of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa, Japan., Yano S; Division of Medical Oncology, Kanazawa University Cancer Research Institute, Kanazawa, Japan., Kirichok Y; Department of Physiology, UCSF, San Francisco, California, USA., Tan DS; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., Rosell R; Germans Trias i Pujol Research Institute and Hospital (IGTP), Badalona, Spain., Okimoto RA; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA., Bivona TG; Department of Medicine and.; Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.; Chan-Zuckerberg Biohub, San Francisco, California, USA.
Source: The Journal of clinical investigation [J Clin Invest] 2022 Jul 01; Vol. 132 (13).
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI145099